- Home
- MNPR vs NVX Comparison
MNPR vs NVX Comparison
Compare MNPR & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- NVX
- Stock Information
- Founded
- MNPR 2014
- NVX 2012
- Country
- MNPR United States
- NVX Australia
- Employees
- MNPR N/A
- NVX N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- NVX Industrial Machinery/Components
- Sector
- MNPR Health Care
- NVX Miscellaneous
- Exchange
- MNPR Nasdaq
- NVX Nasdaq
- Market Cap
- MNPR 209.3M
- NVX 176.8M
- IPO Year
- MNPR 2019
- NVX N/A
- Fundamental
- Price
- MNPR $44.97
- NVX $1.49
- Analyst Decision
- MNPR Strong Buy
- NVX
- Analyst Count
- MNPR 7
- NVX 0
- Target Price
- MNPR $62.00
- NVX N/A
- AVG Volume (30 Days)
- MNPR 69.5K
- NVX 353.9K
- Earning Date
- MNPR 08-08-2025
- NVX 01-01-0001
- Dividend Yield
- MNPR N/A
- NVX N/A
- EPS Growth
- MNPR N/A
- NVX N/A
- EPS
- MNPR N/A
- NVX N/A
- Revenue
- MNPR N/A
- NVX $5,854,424.00
- Revenue This Year
- MNPR N/A
- NVX $66.66
- Revenue Next Year
- MNPR N/A
- NVX $2,366.64
- P/E Ratio
- MNPR N/A
- NVX N/A
- Revenue Growth
- MNPR N/A
- NVX N/A
- 52 Week Low
- MNPR $1.72
- NVX $0.81
- 52 Week High
- MNPR $54.30
- NVX $2.73
- Technical
- Relative Strength Index (RSI)
- MNPR 59.21
- NVX 59.58
- Support Level
- MNPR $44.26
- NVX $1.51
- Resistance Level
- MNPR $47.52
- NVX $2.04
- Average True Range (ATR)
- MNPR 3.49
- NVX 0.17
- MACD
- MNPR 0.54
- NVX 0.04
- Stochastic Oscillator
- MNPR 64.49
- NVX 43.88
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.